First Author: A.K.Cordes GERMANY
Co Author(s): H. Furjani H.R. Koch 0 0 0 0 0 0 0 0 0
Back to previous
Treating Diabetic macular edema requires continuous monitoring and repeated injections of intravitreal medication. Anti-VEGF drugs require close monitoring and often repeated re-injections. Especially international patients cannot adhere to short sequence treatment and control intervals. A safe and long-lasting therapy is essential in achieving good anatomical and functional results.
This study analyses the results of 5 eyes which were treated at the hochkreuz-eye-clinic Bonn from 2011 till today.
We analyzed 5 eyes of 3 patients with long lasting diabetic maculopathy. The initial treatment was initiated with Bevacizumab. This treatment was changed to Ozurdex©-therapy in the course of the treatment.
During the initial Bevacizumab therapy the visual acuity (VA) increased on average -2.43 (+/- 6,4) ETDRS letters. The central retinal thickness (CRT) increased 51.6µm (+/- 106.8). After the switch to the dexamethasone implant the VA increased on average 9.6 (+/- 5.8) EDTRS letters and the CRT decreased -232.4µm (+/- 120.9). The re-injection interval in the Bevacizumab group was greater than 54 days while the Ozurdex©-therapy has to be repeated every 121 days to achieve the result.
The long-lasting dexamethasone implant is a potent drug in treatment of diabetic macular edema. It can lead to anatomical and functional improvement in chronic macular edema even after failure of anti-VEGF therapy. It is a valuable option especially in patients who are depending on less frequent control and treatment intervals.